{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:49:44Z","timestamp":1788324584246,"version":"build-2803163510"},"reference-count":226,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.nano.2026.102935","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:42:33Z","timestamp":1774543353000},"page":"102935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles in oncological therapeutics: Mechanisms of targeted delivery and encapsulation strategies for chemotherapeutics, gene modulators, and phytochemicals"],"prefix":"10.1016","volume":"74","author":[{"given":"Mythileeswari","family":"Lakshmikanthan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakthivel","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathiravan","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar B.","family":"Altemimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek Gamal","family":"Abedelmaksoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2026.102935_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117535","article-title":"Mechanistic study of cancer drug delivery: current techniques, limitations, and future prospects","volume":"290","author":"Imtiaz","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.nano.2026.102935_bb0010","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/gels10080497","article-title":"Development and applications of PLGA hydrogels for sustained delivery of therapeutic agents","volume":"10","author":"Visan","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.nano.2026.102935_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38165","article-title":"The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.nano.2026.102935_bb0020","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/ph16030454","article-title":"Properties of poly (lactic-co-glycolic acid) and progress of poly (lactic-co-glycolic acid)-based biodegradable materials in biomedical research","volume":"16","author":"Lu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nano.2026.102935_bb0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0030","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/pharmaceutics17060682","article-title":"Synergistic cancer therapies enhanced by nanoparticles: advancing nanomedicine through multimodal strategies","volume":"17","author":"Mousavi-Kiasary","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0035","first-page":"295","article-title":"A comprehensive review on advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives","volume":"3","author":"Deivayanai","year":"2024","journal-title":"Cancer Pathog Ther"},{"key":"10.1016\/j.nano.2026.102935_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-022-01320-5","article-title":"Enhancing the therapeutic efficacy of nanoparticles for cancer treatment using versatile targeted strategies","volume":"15","author":"Tian","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0045","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","article-title":"Smart nanoparticles for cancer therapy","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.102935_bb0050","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/nano12030354","article-title":"Recent advances in the surface functionalization of PLGA-based nanomedicines","volume":"12","author":"El-Hammadi","year":"2022","journal-title":"Nanomaterials"},{"key":"10.1016\/j.nano.2026.102935_bb0055","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1039\/C8NH00417J","article-title":"DePEGylation strategies to increase cancer nanomedicine efficacy","volume":"4","author":"Kong","year":"2019","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.nano.2026.102935_bb0060","first-page":"10","article-title":"Development and applications of PLGA hydrogels for sustained delivery of therapeutic agents","author":"Visan","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.nano.2026.102935_bb0065","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/pharmaceutics14030614","article-title":"Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development","volume":"14","author":"Lim","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0070","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.102935_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41392-017-0004-3","article-title":"Controlled drug delivery vehicles for cancer treatment and their performance","volume":"3","author":"Senapati","year":"2018","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.102935_bb0080","doi-asserted-by":"crossref","first-page":"11292","DOI":"10.1038\/s41598-020-68017-y","article-title":"Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles","volume":"10","author":"Norouzi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2026.102935_bb0085","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2026.102935_bb0090","series-title":"Nanostructures for Cancer Therapy","first-page":"775","article-title":"Natural plant-derived anticancer drugs nanotherapeutics: a review on preclinical to clinical success","author":"Varsha","year":"2017"},{"key":"10.1016\/j.nano.2026.102935_bb0095","series-title":"Recent Frontiers of Phytochemicals","first-page":"335","article-title":"Applications of phytochemicals in cancer therapy and anticancer drug development","author":"Puri","year":"2023"},{"key":"10.1016\/j.nano.2026.102935_bb0100","series-title":"Cyclin-Dependent Kinase Inhibitors in Brain cancer: Current State and Future Directions","author":"Juric","year":"2020"},{"key":"10.1016\/j.nano.2026.102935_bb0105","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s43094-024-00727-w","article-title":"Exploring the potential of curcumin-loaded PLGA nanoparticles for angiogenesis and antioxidant proficiency in zebrafish embryo (Danio rerio)","volume":"10","author":"Singha","year":"2024","journal-title":"Futur J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3390\/md21020112","article-title":"Fucoidan in pharmaceutical formulations: a comprehensive review for smart drug delivery systems","volume":"21","author":"Haggag","year":"2023","journal-title":"Mar Drugs"},{"key":"10.1016\/j.nano.2026.102935_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s12951-025-03433-8","article-title":"Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems","volume":"23","author":"Wang","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2026.102935_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117897","article-title":"Exploring the immuno-nano nexus: a paradigm shift in tumor vaccines","volume":"184","author":"Li","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0125","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3390\/polym12061397","article-title":"Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis","volume":"12","author":"Das","year":"2020","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0130","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41120-022-00060-7","article-title":"PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives","volume":"8","author":"Alvi","year":"2022","journal-title":"AAPS Open"},{"key":"10.1016\/j.nano.2026.102935_bb0140","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/polym16091253","article-title":"Application of PLGA in tumor immunotherapy","volume":"16","author":"Wu","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0145","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/10717544.2022.2032878","article-title":"Pharmacodynamics and pharmacokinetics of PLGA-based doxorubicin-loaded implants for tumor therapy","volume":"29","author":"He","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.102935_bb0150","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.102935_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aaz6606","article-title":"Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy","volume":"12","author":"Lu","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.nano.2026.102935_bb0160","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/cancers11050640","article-title":"Active targeting strategies using biological ligands for nanoparticle drug delivery systems","volume":"11","author":"Yoo","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.nano.2026.102935_bb0165","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.2147\/IJN.S219820","article-title":"Co-administration of irgd enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded plga nanoparticles for colorectal cancer treatment","volume":"14","author":"Zhong","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0170","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","article-title":"PLGA-based nanoparticles: an overview of biomedical applications","volume":"161","author":"Danhier","year":"2012","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0175","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/pharmaceutics14122728","article-title":"PLGA-based nanomedicine: history of advancement and development in clinical applications of multiple diseases","volume":"14","author":"Alsaab","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17121613","article-title":"PLGA-based co-delivery nanoformulations: overview, strategies, and recent advances","volume":"17","author":"Stevanovi\u0107","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0185","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/polym16091253","article-title":"Application of PLGA in tumor immunotherapy","volume":"16","author":"Wu","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s13346-023-01413-9","article-title":"Multitarget, multiagent PLGA nanoparticles for simultaneous tumor eradication and TME remodeling in a melanoma mouse model","volume":"14","author":"Ramzy","year":"2023","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.nano.2026.102935_bb0195","article-title":"Hypoxia-responsive self-assembled nanoparticles for reprogramming tumor-associated macrophages into an anti-tumor M1 phenotype in breast cancer","volume":"37","author":"Fu","year":"2026","journal-title":"Mater Today Bio"},{"key":"10.1016\/j.nano.2026.102935_bb0200","first-page":"1","article-title":"PLGA nanoparticles as promising drug delivery carrier: the future of skin cancer treatment","volume":"2025","author":"Todaria","year":"2025","journal-title":"J Umm Al-Qura Univ Appl Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0205","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.1039\/D4CS00421C","article-title":"Lymphoid organ-targeted nanomaterials for immunomodulation of cancer, inflammation, and beyond","volume":"53","author":"Hsu","year":"2024","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nano.2026.102935_bb0210","series-title":"PLGA Nanoparticles as Promising Drug Delivery Carrier: The Future of Skin Cancer Treatment","author":"Todaria","year":"2025"},{"key":"10.1016\/j.nano.2026.102935_bb0215","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.nano.2026.102935_bb0220","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/receptors3030016","article-title":"Receptor-targeted nanomedicine for cancer therapy","volume":"3","author":"Prajapati","year":"2024","journal-title":"Receptors"},{"key":"10.1016\/j.nano.2026.102935_bb0225","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"issue":"1","key":"10.1016\/j.nano.2026.102935_bb0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s12943-025-02410-x","article-title":"PEGylated PLGA nanoparticles: unlocking advanced strategies for cancer therapy","volume":"24","author":"Kesharwani","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nano.2026.102935_bb0235","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/jpm11060571","article-title":"Recent advances in tumor targeting via EPR effect for cancer treatment","volume":"11","author":"Subhan","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.nano.2026.102935_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2020.108805","article-title":"Review of hybrid PLGA nanoparticles: future of smart drug delivery and theranostics medicine","volume":"193","author":"Ghitman","year":"2020","journal-title":"Mater Des"},{"key":"10.1016\/j.nano.2026.102935_bb0245","doi-asserted-by":"crossref","first-page":"7291","DOI":"10.2147\/IJN.S146315","article-title":"Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors","volume":"12","author":"Din","year":"2017","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0250","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/pharmaceutics14020254","article-title":"Encapsulation, release, and cytotoxicity of doxorubicin loaded in liposomes, micelles, and metal-organic frameworks: a review","volume":"14","author":"Ibrahim","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/cancers12010175","article-title":"Polymeric nanoparticles for the treatment of malignant gliomas","volume":"12","author":"Mahmoud","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0260","article-title":"Review article paclitaxel: application in modern oncology and nanomedicine- based","volume":"2021","author":"Sharifi-rad","year":"2021","journal-title":"Cancer Therapy"},{"key":"10.1016\/j.nano.2026.102935_bb0265","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejpb.2006.09.004","article-title":"Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics","volume":"66","author":"Derakhshandeh","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2026.102935_bb0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.7150\/thno.3463","article-title":"Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy","volume":"2","author":"Yu","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.nano.2026.102935_bb0275","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1016\/j.bmc.2011.05.016","article-title":"Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma","volume":"19","author":"Liang","year":"2011","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nano.2026.102935_bb0280","first-page":"1","article-title":"CD44\/folate dual targeting receptor reductive response PLGA-based micelles for cancer therapy","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0285","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ijpharm.2009.10.014","article-title":"LyP-1-conjugated nanoparticles for targeting drug delivery to lymphatic metastatic tumors","volume":"385","author":"Luo","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2006.12.017","article-title":"Anticancer activity of cisplatin-loaded PLGA-mPEG nanoparticles on LNCaP prostate cancer cells","volume":"67","author":"Gryparis","year":"2007","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2026.102935_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.abb.2020.108485","article-title":"Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs","volume":"691","author":"Hashemi","year":"2020","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.nano.2026.102935_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1217769","article-title":"Anti-nucleolin aptamer AS1411: an advancing therapeutic","volume":"10","author":"Van den Avont","year":"2023","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.102935_bb0305","article-title":"Drug-loaded PEG-PLGA nanoparticles for cancer treatment","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0310","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.colsurfb.2014.10.007","article-title":"Enhanced antitumor efficacy of vitamin E TPGS-emulsified PLGA nanoparticles for delivery of paclitaxel","volume":"123","author":"Sun","year":"2014","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.nano.2026.102935_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-023-01865-0","article-title":"Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.nano.2026.102935_bb0320","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small interfering RNA for cancer treatment: overcoming hurdles in delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.nano.2026.102935_bb0325","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbrc.2021.03.086","article-title":"PLGA nanoparticles containing \u03b1-fetoprotein siRNA induce apoptosis and enhance the cytotoxic effects of doxorubicin in human liver cancer cell line","volume":"553","author":"Pho-iam","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.nano.2026.102935_bb0330","doi-asserted-by":"crossref","first-page":"7605","DOI":"10.2147\/IJN.S436038","article-title":"A comprehensive review of small interfering RNAs (siRNAs): mechanism, therapeutic targets, and delivery strategies for cancer therapy","volume":"18","author":"Zhang","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0335","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2796.2009.02189.x","article-title":"Lipid-based nanotherapeutics for siRNA delivery","volume":"267","author":"Schroeder","year":"2010","journal-title":"J Intern Med"},{"key":"10.1016\/j.nano.2026.102935_bb0340","series-title":"Since January 2020 Elsevier Has Created a COVID-19 Resource Centre With Free Information in English and Mandarin on the Novel Coronavirus COVID- 19 The COVID-19 Resource Centre Is Hosted on Elsevier Connect, the Company\u2019s Public News and Information","author":"Guo","year":"2020"},{"key":"10.1016\/j.nano.2026.102935_bb0345","series-title":"Nanoparticle-based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance","first-page":"1","volume":"7","author":"Yao","year":"2020"},{"key":"10.1016\/j.nano.2026.102935_bb0350","series-title":"Targeted siRNA Lipid Nanoparticles for the Treatment of KRAS-mutant Tumors","first-page":"67","volume":"357","author":"Isabel","year":"2023"},{"key":"10.1016\/j.nano.2026.102935_bb0355","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1080\/10717544.2022.2089296","article-title":"Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems","volume":"29","author":"Bajracharya","year":"2022","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.102935_bb0360","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/09687688.2010.521200","article-title":"Receptor-targeted nanocarriers for therapeutic delivery to cancer","volume":"27","author":"Yu","year":"2010","journal-title":"Mol Membr Biol"},{"key":"10.1016\/j.nano.2026.102935_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discovery"},{"key":"10.1016\/j.nano.2026.102935_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming cancer multi-drug resistance (MDR): reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0375","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3390\/molecules27196608","article-title":"Role of nanotechnology in overcoming the multidrug resistance in cancer therapy: a review","volume":"27","author":"Mir","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2026.102935_bb0380","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/polym16091253","article-title":"Application of PLGA in tumor immunotherapy","volume":"16","author":"Wu","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2023.117263","article-title":"Nano-scale delivery systems for siRNA delivery in cancer therapy: new era of gene therapy empowered by nanotechnology","volume":"239","author":"Ebrahimi","year":"2023","journal-title":"Environ Res"},{"key":"10.1016\/j.nano.2026.102935_bb0390","article-title":"The strategies and advances of mRNA translation booster","volume":"20","author":"Shi","year":"2025","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0395","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20160616","article-title":"Cytoplasmic transport and nuclear import of plasmid DNA","volume":"37","author":"Bai","year":"2017","journal-title":"Biosci Rep"},{"key":"10.1016\/j.nano.2026.102935_bb0400","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01260","article-title":"PLGA-based nanoparticles in cancer treatment","volume":"9","author":"Rezvantalab","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2014.11.019","article-title":"Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance","volume":"198","author":"Yhee","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0410","doi-asserted-by":"crossref","first-page":"986","DOI":"10.20892\/j.issn.2095-3941.2020.0128","article-title":"HM30181A, a potent P-glycoprotein inhibitor, potentiates the absorption and in vivo antitumor efficacy of paclitaxel in an orthotopic brain tumor model","volume":"17","author":"Zeng","year":"2020","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.nano.2026.102935_bb0415","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.3390\/ijms19103264","article-title":"Nanoparticle-mediated combination therapy: two-in-one approach for cancer","volume":"19","author":"Gurunathan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0420","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/17425247.2016.1205583","article-title":"Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy","volume":"14","author":"Xiao","year":"2017","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2026.102935_bb0425","article-title":"Nucleic acid strategies for infectious disease treatments: the nanoparticle-based oral delivery route","volume":"13","author":"Chen","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0430","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1007\/s11051-014-2682-x","article-title":"Antitumor effects of MsurvivinT34A\u2013CaPi complex-embedded PLGA nanoparticles in combination with Doxil in mice","volume":"16","author":"Tang","year":"2014","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.nano.2026.102935_bb0435","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.2147\/IJN.S321329","article-title":"Recent advances and challenges in gene delivery mediated by polyester-based nanoparticles","volume":"16","author":"Piperno","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0440","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.3390\/ijms23126386","article-title":"CRISPR\/Cas9-directed gene trap constitutes a selection system for corrected BCR\/ABL leukemic cells in CML","volume":"23","author":"Vuelta","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0445","first-page":"487","article-title":"Current applications and future prospects of nanotechnology in cancer immunotherapy, cancer","volume":"16","author":"Yan","year":"2019","journal-title":"Biol Med"},{"key":"10.1016\/j.nano.2026.102935_bb0450","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.3390\/cancers12123773","article-title":"Cancer immunotherapy and application of nanoparticles in cancers immunotherapy as the delivery of immunotherapeutic agents and as the immunomodulators","volume":"12","author":"Debele","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0455","first-page":"1","article-title":"Immune-regulating camouflaged nanoplatforms: a promising strategy to improve cancer nano-immunotherapy","volume":"21","author":"Chen","year":"2023","journal-title":"Bioact Mater"},{"key":"10.1016\/j.nano.2026.102935_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2024.115342","article-title":"Modulating the immune system towards a functional chronic wound healing: a biomaterials and nanomedicine perspective","volume":"210","author":"Las Heras","year":"2024","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nano.2026.102935_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.973666","article-title":"Poly lactic-co-glycolic acid-based nanoparticles as delivery systems for enhanced cancer immunotherapy","volume":"10","author":"Gao","year":"2022","journal-title":"Front Chem"},{"key":"10.1016\/j.nano.2026.102935_bb0470","article-title":"A bibliometric insight into nanomaterials in vaccine: trends, collaborations, and future avenues","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2026.102935_bb0475","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12951-024-02758-0","article-title":"Tailoring biomaterials for vaccine delivery","volume":"22","author":"Zhuo","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.nano.2026.102935_bb0480","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.biomaterials.2018.03.036","article-title":"Engineering nanoparticle strategies for effective cancer immunotherapy","volume":"178","author":"Yoon","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2026.102935_bb0485","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrd.2017.34","article-title":"Lessons from immuno-oncology: a new era for cancer nanomedicine?","volume":"16","author":"Jiang","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nano.2026.102935_bb0490","doi-asserted-by":"crossref","first-page":"0029","DOI":"10.1038\/s41551-017-0029","article-title":"Designing nanomedicine for immuno-oncology","volume":"1","author":"Jiang","year":"2017","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.nano.2026.102935_bb0495","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.vaccine.2014.12.059","article-title":"Poly-(lactic-co-glycolic-acid)-based particulate vaccines: particle uptake by dendritic cells is a key parameter for immune activation","volume":"33","author":"Silva","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.nano.2026.102935_bb0500","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1021\/acs.molpharmaceut.3c00330","article-title":"Controlling antigen fate in therapeutic cancer vaccines by targeting dendritic cell receptors","volume":"20","author":"Wijfjes","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0505","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/acs.molpharmaceut.7b00795","article-title":"Poly(I:C)-encapsulating nanoparticles enhance innate immune responses to the tuberculosis vaccine Bacille Calmette\u2013Gu\u00e9rin (BCG) via synergistic activation of innate immune receptors","volume":"14","author":"Speth","year":"2017","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38165","article-title":"The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.nano.2026.102935_bb0515","article-title":"Nanoprecipitation-induced formation of nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2026","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0520","article-title":"Sustained and targeted delivery of hydrophilic drug compounds: a review of existing and novel technologies from bench to bedside","volume":"78","author":"Hardenia","year":"2022","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.nano.2026.102935_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38165","article-title":"The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers","volume":"10","author":"Sun","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.nano.2026.102935_bb0530","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41120-022-00060-7","article-title":"PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives","volume":"8","author":"Alvi","year":"2022","journal-title":"AAPS Open"},{"key":"10.1016\/j.nano.2026.102935_bb0535","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2026.102935_bb0540","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3390\/jpm11080771","article-title":"The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application","volume":"11","author":"Wu","year":"2021","journal-title":"J Pers Med"},{"key":"10.1016\/j.nano.2026.102935_bb0545","article-title":"Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles","volume":"8","author":"Prielo\u017en\u00e1","year":"2024","journal-title":"Int J Pharm X"},{"key":"10.1016\/j.nano.2026.102935_bb0550","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2026.102935_bb0555","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.nano.2026.102935_bb0560","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172513","article-title":"Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy","volume":"859","author":"Negrette-Guzm\u00e1n","year":"2019","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0570","doi-asserted-by":"crossref","first-page":"8073","DOI":"10.2147\/IJN.S220740","article-title":"CD-340 functionalized doxorubicin-loaded nanoparticle induces apoptosis and reduces tumor volume along with drug-related cardiotoxicity in mice","volume":"14","author":"Mondal","year":"2019","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0575","first-page":"167","article-title":"RETRACTED ARTICLE: co-delivery of doxorubicin and SIS3 by folate-targeted polymeric micelles for overcoming tumor multidrug resistance, drug Deliv","volume":"12","author":"Wang","year":"2022","journal-title":"Transl Res"},{"key":"10.1016\/j.nano.2026.102935_bb0580","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.actbio.2021.11.050","article-title":"Stimuli-responsive, dual-function prodrug encapsulated in hyaluronic acid micelles to overcome doxorubicin resistance","volume":"140","author":"Qiu","year":"2022","journal-title":"Acta Biomater"},{"key":"10.1016\/j.nano.2026.102935_bb0585","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11051-020-04798-7","article-title":"Transferrin-conjugated doxorubicin-loaded PLGA nanoparticles with pH-responsive behavior: a synergistic approach for cancer therapy","volume":"22","author":"Scheeren","year":"2020","journal-title":"J Nanopart Res"},{"key":"10.1016\/j.nano.2026.102935_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.nano.2026.102935_bb0595","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s40001-024-01657-2","article-title":"Paclitaxel and its semi-synthetic derivatives: comprehensive insights into chemical structure, mechanisms of action, and anticancer properties","volume":"29","author":"Sati","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.nano.2026.102935_bb0600","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1039\/D1MA00961C","article-title":"Recent advances in the targeted delivery of paclitaxel nanomedicine for cancer therapy","volume":"3","author":"Raza","year":"2022","journal-title":"Mater Adv"},{"key":"10.1016\/j.nano.2026.102935_bb0605","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2008.09.086","article-title":"Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation","volume":"133","author":"Danhier","year":"2009","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0610","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jconrel.2005.08.013","article-title":"Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin","volume":"108","author":"Mo","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0615","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40199-015-0107-8","article-title":"Improved anticancer delivery of paclitaxel by albumin surface modification of PLGA nanoparticles","volume":"23","author":"Esfandyari-Manesh","year":"2015","journal-title":"DARU J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0620","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.msec.2017.03.121","article-title":"Development of biodegradable PLGA nanoparticles surface engineered with hyaluronic acid for targeted delivery of paclitaxel to triple negative breast cancer cells","volume":"76","author":"Cerqueira","year":"2017","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.nano.2026.102935_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2019.110576","article-title":"Lipid-PLGA hybrid nanoparticles of paclitaxel: preparation, characterization, in vitro and in vivo evaluation","volume":"109","author":"Godara","year":"2020","journal-title":"Mater Sci Eng C"},{"key":"10.1016\/j.nano.2026.102935_bb0630","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijpharm.2007.04.031","article-title":"Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles prepared by high pressure homogenization for paclitaxel chemotherapy","volume":"342","author":"Dong","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0635","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0168-3659(02)00212-2","article-title":"Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity","volume":"83","author":"Fonseca","year":"2002","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0640","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s11095-009-9889-z","article-title":"Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells","volume":"26","author":"Jin","year":"2009","journal-title":"Pharm Res"},{"key":"10.1016\/j.nano.2026.102935_bb0645","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/j.ijbiomac.2020.07.228","article-title":"Synthesis of PLGA\/chitosan\/zeolites and PLGA\/chitosan\/metal organic frameworks nanofibers for targeted delivery of paclitaxel toward prostate cancer cells death","volume":"164","author":"Faraji Dizaji","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.nano.2026.102935_bb0650","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1039\/C9CS00839J","article-title":"Stimuli-responsive nanobubbles for biomedical applications","volume":"50","author":"Xiong","year":"2021","journal-title":"Chem Soc Rev"},{"key":"10.1016\/j.nano.2026.102935_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfa.2020.125669","article-title":"Stability of nanobubbles in different salts solutions","volume":"609","author":"Hewage","year":"2021","journal-title":"Colloids Surf A Physicochem Eng Asp"},{"key":"10.1016\/j.nano.2026.102935_bb0660","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1021\/acsnano.0c07674","article-title":"Imaging and quantifying the formation of single nanobubbles at single platinum nanoparticles during the hydrogen evolution reaction","volume":"15","author":"Lemineur","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.nano.2026.102935_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.cocis.2021.101455","article-title":"Bulk nanobubbles, generation methods and potential applications","volume":"54","author":"Favvas","year":"2021","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0670","doi-asserted-by":"crossref","first-page":"32763","DOI":"10.1021\/acsami.1c07323","article-title":"Immune\/hypoxic tumor microenvironment regulation-enhanced photodynamic treatment realized by pH-responsive phase transition-targeting nanobubbles","volume":"13","author":"Zhao","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2026.102935_bb0675","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijpharm.2013.05.018","article-title":"Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells","volume":"454","author":"Le Broc-Ryckewaert","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0680","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jconrel.2016.04.019","article-title":"Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer","volume":"232","author":"Adjei","year":"2016","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0685","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2148-14-10","article-title":"Phylogenetic analysis of CDK and cyclin proteins in premetazoan lineages","volume":"14","author":"Cao","year":"2014","journal-title":"BMC Evol Biol"},{"key":"10.1016\/j.nano.2026.102935_bb0690","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231205848","article-title":"CDK4\/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity \u2013 a narrative review","volume":"15","author":"Pavlovic","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0695","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00432-011-1039-4","article-title":"The CDK inhibitors in cancer research and therapy","volume":"137","author":"Cicenas","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128821","article-title":"Design, development, and evaluation of CDK-4\/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer","volume":"258","author":"Pooja","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.nano.2026.102935_bb0705","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.3390\/ijms21061960","article-title":"The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast Cancer","volume":"21","author":"Ding","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0710","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1158\/0008-5472.CAN-03-0110","article-title":"The cyclin-dependent kinase inhibitor CYC202 (R-Roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of cyclin D1, and activates the mitogen-activated protein kinase pathway","volume":"64","author":"Whittaker","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2026.102935_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116207","article-title":"Unveiling the potential effects of resveratrol in lung cancer treatment: mechanisms and nanoparticle-based drug delivery strategies","volume":"172","author":"Najafiyan","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0720","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor\u2013positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2026.102935_bb0725","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nano.2026.102935_bb0730","first-page":"65","article-title":"Targeting the cyclin D-cyclin-dependent kinase (CDK) 4\/6-retinoblastoma pathway with selective CDK 4\/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions","volume":"21","author":"Spring","year":"2016","journal-title":"Discov Med"},{"key":"10.1016\/j.nano.2026.102935_bb0735","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-09-4559","article-title":"Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts","volume":"70","author":"Michaud","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2026.102935_bb0740","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2015.00259","article-title":"CDK4\/6 inhibitor PD0332991 in glioblastoma treatment: does it have a future?","volume":"5","author":"Schr\u00f6der","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077639","article-title":"PD-0332991, a CDK4\/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma","volume":"8","author":"Barton","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2026.102935_bb0750","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s10637-015-0266-y","article-title":"P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4\/6 inhibitor palbociclib","volume":"33","author":"de Gooijer","year":"2015","journal-title":"Investig New Drugs"},{"key":"10.1016\/j.nano.2026.102935_bb0755","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/neuonc\/nov164","article-title":"Strategies to improve delivery of anticancer drugs across the blood\u2013brain barrier to treat glioblastoma","volume":"18","author":"Oberoi","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.nano.2026.102935_bb0760","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13045-022-01344-x","article-title":"Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of molecular tumor board combination strategy resulting in long-term exceptional response","volume":"15","author":"Persha","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0765","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.2147\/IJN.S258699","article-title":"Enhanced anti-brain metastasis from non-small cell lung cancer of osimertinib and doxorubicin co-delivery targeted nanocarrier","volume":"15","author":"Wang","year":"2020","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0770","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-023-04257-y","article-title":"T7 peptide - decorated exosome - based nanocarrier system for delivery of galectin - 9 siRNA to stimulate macrophage repolarization in glioblastoma","volume":"162","author":"Li","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.nano.2026.102935_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122443","article-title":"5-fluorouracil crystal-incorporated, pH-responsive, and release-modulating PLGA\/Eudragit FS hybrid microparticles for local colorectal cancer-targeted chemotherapy","volume":"630","author":"Lee","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0780","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.xphs.2018.10.042","article-title":"Dual-targeting nanoparticles: codelivery of curcumin and 5-fluorouracil for synergistic treatment of hepatocarcinoma","volume":"108","author":"Ni","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0785","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.colsurfb.2017.04.020","article-title":"Stealth recombinant human serum albumin nanoparticles conjugating 5-fluorouracil augmented drug delivery and cytotoxicity in human colon cancer, HT-29 cells","volume":"155","author":"Sharma","year":"2017","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.nano.2026.102935_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111285","article-title":"5-fluorouracil (5-FU) resistance and the new strategy to enhance the sensitivity against cancer: implication of DNA repair inhibition","volume":"137","author":"Sethy","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0795","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.1021\/acs.langmuir.7b03173","article-title":"Lyotropic liquid-crystalline nanosystems as drug delivery agents for 5-fluorouracil: structure and cytotoxicity","volume":"33","author":"Astolfi","year":"2017","journal-title":"Langmuir"},{"key":"10.1016\/j.nano.2026.102935_bb0800","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40204-018-0104-3","article-title":"Synergistic delivery of 5-fluorouracil and curcumin using human serum albumin-coated iron oxide nanoparticles by folic acid targeting","volume":"7","author":"Hiremath","year":"2018","journal-title":"Prog Biomater"},{"key":"10.1016\/j.nano.2026.102935_bb0805","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/s12885-020-06803-7","article-title":"Enhanced antitumor efficacy in colon cancer using EGF functionalized PLGA nanoparticles loaded with 5-fluorouracil and perfluorocarbon","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nano.2026.102935_bb0810","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijpharm.2012.07.006","article-title":"PEGylated-PLGA microparticles containing VEGF for long term drug delivery","volume":"440","author":"Sim\u00f3n-Yarza","year":"2013","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0815","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000091308","article-title":"Sunflower seed oil-enriched product can inhibit Ehrlich solid tumor growth in mice","volume":"52","author":"Silva","year":"2006","journal-title":"Chemotherapy"},{"key":"10.1016\/j.nano.2026.102935_bb0820","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopha.2018.05.124","article-title":"Polymeric nano-encapsulation of 5-fluorouracil enhances anti-cancer activity and ameliorates side effects in solid Ehrlich carcinoma-bearing mice","volume":"105","author":"Haggag","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0825","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.3748\/wjg.v9.i8.1795","article-title":"Toxicities and therapeutic effect of 5-fluorouracil controlled release implant on tumor-bearing rats","volume":"9","author":"He","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.nano.2026.102935_bb0830","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2009.10.005","article-title":"Pharmacodynamics of cisplatin-loaded PLGA nanoparticles administered to tumor-bearing mice","volume":"74","author":"Moreno","year":"2010","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2026.102935_bb0835","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.colsurfb.2019.03.011","article-title":"Cisplatin-loaded PLGA nanoparticles for HER2 targeted ovarian cancer therapy","volume":"178","author":"Dom\u00ednguez-R\u00edos","year":"2019","journal-title":"Colloids Surf B: Biointerfaces"},{"key":"10.1016\/j.nano.2026.102935_bb0840","doi-asserted-by":"crossref","first-page":"5834418","DOI":"10.1155\/2021\/5834418","article-title":"Poly lactic-co-glycolic acid- (PLGA-) loaded nanoformulation of cisplatin as a therapeutic approach for breast cancers","volume":"2021","author":"Alkahtani","year":"2021","journal-title":"Oxidative Med Cell Longev"},{"key":"10.1016\/j.nano.2026.102935_bb0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081162","article-title":"Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions","volume":"8","author":"Marullo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nano.2026.102935_bb0850","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.2147\/IJN.S298252","article-title":"TMTP1-modified, tumor microenvironment responsive nanoparticles co-deliver cisplatin and paclitaxel prodrugs for effective cervical cancer therapy","volume":"16","author":"Jiang","year":"2021","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0855","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","article-title":"Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine","volume":"22","author":"Dhyani","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.nano.2026.102935_bb0860","series-title":"Comprehensive Gynecology","first-page":"618","article-title":"Principles of radiation therapy and chemotherapy in gynecologic cancer","author":"Smith","year":"2022"},{"key":"10.1016\/j.nano.2026.102935_bb0865","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00280-012-2042-4","article-title":"Marqibo\u00ae (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine","volume":"71","author":"Silverman","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.nano.2026.102935_bb0870","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fmolb.2020.00193","article-title":"Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance","volume":"7","author":"Yao","year":"2020","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.nano.2026.102935_bb0875","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.chroma.2012.12.026","article-title":"Determination of free and total vincristine in human plasma after intravenous administration of vincristine sulfate liposome injection using ultra-high performance liquid chromatography tandem mass spectrometry","volume":"1275","author":"Yang","year":"2013","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.nano.2026.102935_bb0880","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1002\/jbm.a.34890","article-title":"Improved brain delivery of vincristine using dextran sulfate complex solid lipid nanoparticles: optimization and in vivo evaluation","volume":"102","author":"Aboutaleb","year":"2014","journal-title":"J Biomed Mater Res A"},{"key":"10.1016\/j.nano.2026.102935_bb0885","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/elps.201300185","article-title":"Synthesis of uniform poly(d,l-lactide) and poly(d,l-lactide- co -glycolide) microspheres using a microfluidic chip for comparison","volume":"35","author":"Yang","year":"2014","journal-title":"Electrophoresis"},{"key":"10.1016\/j.nano.2026.102935_bb0890","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1039\/B814952F","article-title":"Microfluidic assisted synthesis of multi-functional polycaprolactone microcapsules: incorporation of CdTe quantum dots, Fe 3 O 4 superparamagnetic nanoparticles and tamoxifen anticancer drugs","volume":"9","author":"Yang","year":"2009","journal-title":"Lab Chip"},{"key":"10.1016\/j.nano.2026.102935_bb0895","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.3390\/molecules18066521","article-title":"A microfluidic chip using phenol formaldehyde resin for uniform-sized polycaprolactone and chitosan microparticle generation","volume":"18","author":"Lin","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2026.102935_bb0900","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/s120201455","article-title":"An aluminum microfluidic chip fabrication using a convenient micromilling process for fluorescent poly(DL-lactide-co-glycolide) microparticle generation","volume":"12","author":"Lin","year":"2012","journal-title":"Sensors"},{"key":"10.1016\/j.nano.2026.102935_bb0905","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.ejps.2012.07.002","article-title":"Folic acid and cell-penetrating peptide conjugated PLGA\u2013PEG bifunctional nanoparticles for vincristine sulfate delivery","volume":"47","author":"Chen","year":"2012","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0910","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jconrel.2010.08.010","article-title":"Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition","volume":"148","author":"Ling","year":"2010","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb0915","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1016\/j.biomaterials.2011.04.022","article-title":"Multifunctional nanoassemblies for vincristine sulfate delivery to overcome multidrug resistance by escaping P-glycoprotein mediated efflux","volume":"32","author":"Zhang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.nano.2026.102935_bb0920","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.3390\/pharmaceutics15122728","article-title":"Podophyllotoxin: recent advances in the development of hybridization strategies to enhance its antitumoral profile","volume":"15","author":"Miranda-Vera","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb0925","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3390\/biom11040603","article-title":"Podophyllotoxin: history, recent advances and future prospects","volume":"11","author":"Shah","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.nano.2026.102935_bb0930","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/polym16060843","article-title":"Polymer-based drug delivery systems for cancer therapeutics","volume":"16","author":"Ding","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114145","article-title":"Podophyllotoxin and its derivatives: potential anticancer agents of natural origin in cancer chemotherapy","volume":"158","author":"Motyka","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.nano.2026.102935_bb0940","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/ddr.20365","article-title":"Long circulating nanoparticles of etoposide using PLGA-MPEG and PLGA-pluronic block copolymers: characterization, drug-release, blood-clearance, and biodistribution studies","volume":"71","author":"Yadav","year":"2010","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.nano.2026.102935_bb0945","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12645-012-0027-y","article-title":"PLGA nanoparticles loaded with etoposide and quercetin dihydrate individually: in vitro cell line study to ensure advantage of combination therapy","volume":"3","author":"Pimple","year":"2012","journal-title":"Cancer Nanotechnol"},{"key":"10.1016\/j.nano.2026.102935_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2021.102582","article-title":"Curcumin encapsulation in functional PLGA nanoparticles: a promising strategy for cancer therapies","volume":"300","author":"Feltrin","year":"2022","journal-title":"Adv Colloid Interf Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0955","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2217\/nnm-2021-0066","article-title":"Effects of curcumin-loaded poly(lactic-co-glycolic acid) nanoparticles in MDA-MB231 human breast cancer cells","volume":"16","author":"Sharma","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb0960","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.3390\/molecules27165236","article-title":"Curcumin-based nanoformulations: a promising adjuvant towards cancer treatment","volume":"27","author":"Hafez Ghoran","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2026.102935_bb0965","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1535-7163.MCT-10-0172","article-title":"Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer","volume":"9","author":"Bisht","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.nano.2026.102935_bb0970","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1208\/s12248-015-9811-z","article-title":"Therapeutic applications of curcumin nanoformulations","volume":"17","author":"Yallapu","year":"2015","journal-title":"AAPS J"},{"key":"10.1016\/j.nano.2026.102935_bb0975","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1021\/mp500222k","article-title":"Antiproliferative effect of ASC-J9 delivered by PLGA nanoparticles against estrogen-dependent breast cancer cells","volume":"11","author":"Verderio","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb0980","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/ijms20051033","article-title":"A review of curcumin and its derivatives as anticancer agents","volume":"20","author":"Tomeh","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nano.2026.102935_bb0985","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40820-021-00622-6","article-title":"Recent advancements in nanomedicine for \u2018cold\u2019 tumor immunotherapy","volume":"13","author":"Chen","year":"2021","journal-title":"Nano Lett"},{"key":"10.1016\/j.nano.2026.102935_bb0990","first-page":"3358","article-title":"Polysaccharide-based nanomedicines for cancer immunotherapy: a review","volume":"6","author":"Zeng","year":"2021","journal-title":"Bioact Mater"},{"key":"10.1016\/j.nano.2026.102935_bb0995","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122407","article-title":"The application of marine polysaccharides to antitumor nanocarriers","volume":"342","author":"Wang","year":"2024","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.nano.2026.102935_bb1000","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.2147\/IJN.S423412","article-title":"Algae: a robust living material against cancer","volume":"18","author":"Xin","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2026.102935_bb1005","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3390\/md21050307","article-title":"Ten years of research on fucoidan and cancer: focus on its antiangiogenic and antimetastatic effects","volume":"21","author":"Turrini","year":"2023","journal-title":"Mar Drugs"},{"key":"10.1016\/j.nano.2026.102935_bb1010","doi-asserted-by":"crossref","DOI":"10.1186\/s40169-019-0234-9","article-title":"Clinical applications of fucoidan in translational medicine for adjuvant cancer therapy","volume":"8","author":"Hsu","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.nano.2026.102935_bb1015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3390\/md21020128","article-title":"Immunopotentiating activity of fucoidans and relevance to cancer immunotherapy","volume":"21","author":"Li","year":"2023","journal-title":"Mar Drugs"},{"key":"10.1016\/j.nano.2026.102935_bb1020","doi-asserted-by":"crossref","first-page":"970","DOI":"10.3390\/biom10070970","article-title":"Development and characterization of a fucoidan-based drug delivery system by using hydrophilic anticancer polysaccharides to simultaneously deliver hydrophobic anticancer drugs","volume":"10","author":"Lai","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.nano.2026.102935_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126211","article-title":"Fucoidan\/chitosan layered PLGA nanoparticles with melatonin loading for inducing intestinal absorption and addressing triple-negative breast cancer progression","volume":"250","author":"Yen","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.nano.2026.102935_bb1030","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.3390\/ph18121772","article-title":"Advances in lipid-polymer hybrid nanoparticles: design strategies, functionalization, oncological and non-oncological clinical prospects","volume":"18","author":"Jacob","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.nano.2026.102935_bb1035","doi-asserted-by":"crossref","DOI":"10.1016\/j.glmedi.2024.100163","article-title":"Role of folate receptor and CD44 in targeting of docetaxel and paclitaxel fabricated conjugates for efficient cancer therapy","volume":"5","author":"Tatode","year":"2025","journal-title":"J Med Surg Public Health"},{"key":"10.1016\/j.nano.2026.102935_bb1040","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijpharm.2018.04.062","article-title":"Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment","volume":"545","author":"Ramalho","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2026.102935_bb1045","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jconrel.2016.12.024","article-title":"Hyaluronic acid coated PLGA nanoparticulate docetaxel effectively targets and suppresses orthotopic human lung cancer","volume":"259","author":"Wu","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb1050","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.apsb.2019.06.004","article-title":"Development and application of hyaluronic acid in tumor targeting drug delivery","volume":"9","author":"Luo","year":"2019","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.nano.2026.102935_bb1055","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jconrel.2024.10.037","article-title":"Recent advances in liposomes and peptide-based therapeutics for glioblastoma treatment","volume":"376","author":"Jourdain","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2026.102935_bb1060","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3390\/molecules23040830","article-title":"Applications of cancer cell-specific aptamers in targeted delivery of anticancer therapeutic agents","volume":"23","author":"Kim","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2026.102935_bb1065","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41392-024-02035-4","article-title":"Nucleic acid drugs: recent progress and future perspectives","volume":"9","author":"Sun","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.nano.2026.102935_bb1070","first-page":"687","article-title":"Applications and developments of gene therapy drug delivery systems for genetic diseases","volume":"16","author":"Pan","year":"2021","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.nano.2026.102935_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104702","article-title":"A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors","volume":"210","author":"Liu","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.nano.2026.102935_bb1080","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/pharmaceutics15020615","article-title":"PLGA particles in immunotherapy","volume":"15","author":"Horvath","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb1085","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100178","article-title":"Phytonanomedicine: a therapeutic approach for cervical cancer","volume":"13","author":"Parveen","year":"2023","journal-title":"OpenNano"},{"key":"10.1016\/j.nano.2026.102935_bb1090","article-title":"A doxorubicin and siRNA coloaded nanolamellar hydroxyapatite\/PLGA electrospun scaffold as a safe antitumor drug delivery system","volume":"31","author":"Zhu","year":"2023","journal-title":"Appl Mater Today"},{"key":"10.1016\/j.nano.2026.102935_bb1095","doi-asserted-by":"crossref","first-page":"32159","DOI":"10.1021\/acsami.6b10175","article-title":"Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy","volume":"8","author":"Cui","year":"2016","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.nano.2026.102935_bb1100","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/pharmaceutics14071326","article-title":"PLGA-quercetin Nano-formulation inhibits cancer progression via mitochondrial dependent caspase-3,7 and independent FoxO1 activation with concomitant PI3K\/AKT suppression","volume":"14","author":"Yadav","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb1105","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.3390\/molecules26195905","article-title":"Controlled drug delivery systems: current status and future directions","volume":"26","author":"Adepu","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2026.102935_bb1110","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.3390\/pharmaceutics14112520","article-title":"siRNA functionalized lipid nanoparticles (LNPs) in management of diseases","volume":"14","author":"Kalita","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.nano.2026.102935_bb1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2025.102645","article-title":"Nanogels: a chemically versatile drug delivery platform","volume":"61","author":"Blagojevic","year":"2025","journal-title":"Nano Today"},{"key":"10.1016\/j.nano.2026.102935_bb1120","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.3390\/polym16182606","article-title":"Recent applications of PLGA in drug delivery systems","volume":"16","author":"Yang","year":"2024","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.nano.2026.102935_bb1125","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/10717544.2021.1938756","article-title":"PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application","volume":"28","author":"Su","year":"2021","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2026.102935_bb1130","doi-asserted-by":"crossref","first-page":"1670397","DOI":"10.3389\/fphar.2025.1670397","article-title":"Multifunctional PLGA nanosystems: enabling integrated diagnostic and therapeutic strategies","volume":"16","author":"Li","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963426000365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T22:29:13Z","timestamp":1785709753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963426000365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":226,"alternative-id":["S1549963426000365"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2026.102935","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles in oncological therapeutics: Mechanisms of targeted delivery and encapsulation strategies for chemotherapeutics, gene modulators, and phytochemicals","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2026.102935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102935"}}